FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1905936601> ?p ?o ?g. }

• W1905936601 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CAThe rapidly growing field of Antibody-Drug Conjugates (ADCs) has recently spurred the study of novel drug payloads. In particular, much interest has been paid to the identification of novel cytotoxic agents, which differ in mechanism from anti-tubulin agents, currently the most commonly employed class of drug for ADC coupling. Novel drug payloads for ADC-based therapy should thus ideally possess highly potent cytotoxic activity with a diverse mechanism from tubulin agents, as well as physicochemical properties, which facilitate coupling to antibodies. Duocarmycins are a widely-described class of DNA minor groove binding alkylating agents, examples of which can exhibit picomolar activity against human tumor cell lines, as well as high activity in preclinical tumor models. The clinical development of duocarmycins as drugs in their own right has however been hampered by an extremely limited therapeutic window. Duocarmycins also typically exhibit poor physicochemical profiles, most importantly generally possessing limited aqueous solubility and a propensity to induce protein aggregation, which renders these molecules poorly tractable as optimal ADC payloads. Based on the premise that opportune modification of the duocarmycin scaffold could lead to the discovery of compounds better suited to antibody conjugation, we describe the identification and related proof of concept studies for a novel chemical series based on a proprietary thienoindole scaffold, characterized both by potent antitumor activity and by physicochemical properties that are highly compatible with deployment as antibody payloads.Extensive in vitro profiling within the thienoindole series led to selection of potent cytotoxic compounds suitable for test conjugation to humanized monoclonal antibodies, which were then submitted to in vitro/in vivo profiling. Typically, average drug/antibody ratios (DARs) of 4 could readily be achieved without induction of antibody aggregation/precipitation and without affecting natural antibody-ligand affinity. Efficacy and mechanism of action studies were carried out for thienoindole-ADCs prepared with trastuzumab and with rituximab showing target driven effects in Her2 positive vs. negative breast cancer cell lines and against CD20 positive vs. negative hematological cell lines. PK data indicated long, essentially unaffected plasma half life of our novel ADCs in the mouse. In vivo efficacy studies in the Her2-positive HCC1954 human breast cancer model showed complete tumor regression in mice treated with trastuzumab-ADC with no effects on body weight gain, while unarmed trastuzumab and armed control antibody had little and no effect, respectively.Citation Format: Barbara Valsasina, Fabio Gasparri, Italo Beria, Nicoletta Colombo, Paolo Orsini, Rita Perego, Simona Rizzi, Ulisse Cucchi, Clara Albanese, Aurelio Marsiglio, Ivan Fraietta, Marina Ciomei, Sabrina Cribioli, Carlo Visco, Eduard R. Felder, Antonella Isacchi, Enrico A. Pesenti, Arturo Galvani, Daniele Donati, Michele Caruso. Thienoindoles, a novel class of DNA minor groove alkylating agents highly suited for the generation of novel antibody drug conjugates (ADCs). [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 822. doi:10.1158/1538-7445.AM2014-822" @default.
• W1905936601 created "2016-06-24" @default.
• W1905936601 creator A5000499660 @default.
• W1905936601 creator A5005794932 @default.
• W1905936601 creator A5008691829 @default.
• W1905936601 creator A5025261960 @default.
• W1905936601 creator A5028520464 @default.
• W1905936601 creator A5032826890 @default.
• W1905936601 creator A5036707826 @default.
• W1905936601 creator A5041326568 @default.
• W1905936601 creator A5044377393 @default.
• W1905936601 creator A5049953201 @default.
• W1905936601 creator A5051084648 @default.
• W1905936601 creator A5061258831 @default.
• W1905936601 creator A5062095629 @default.
• W1905936601 creator A5066888430 @default.
• W1905936601 creator A5068718640 @default.
• W1905936601 creator A5082419868 @default.
• W1905936601 creator A5083934929 @default.
• W1905936601 creator A5084826357 @default.
• W1905936601 creator A5087080299 @default.
• W1905936601 creator A5088676411 @default.
• W1905936601 date "2014-09-30" @default.
• W1905936601 modified "2023-09-27" @default.
• W1905936601 title "Abstract 822: Thienoindoles, a novel class of DNA minor groove alkylating agents highly suited for the generation of novel antibody drug conjugates (ADCs)" @default.
• W1905936601 doi "https://doi.org/10.1158/1538-7445.am2014-822" @default.
• W1905936601 hasPublicationYear "2014" @default.
• W1905936601 type Work @default.
• W1905936601 sameAs 1905936601 @default.
• W1905936601 citedByCount "1" @default.
• W1905936601 countsByYear W19059366012019 @default.
• W1905936601 crossrefType "proceedings-article" @default.
• W1905936601 hasAuthorship W1905936601A5000499660 @default.
• W1905936601 hasAuthorship W1905936601A5005794932 @default.
• W1905936601 hasAuthorship W1905936601A5008691829 @default.
• W1905936601 hasAuthorship W1905936601A5025261960 @default.
• W1905936601 hasAuthorship W1905936601A5028520464 @default.
• W1905936601 hasAuthorship W1905936601A5032826890 @default.
• W1905936601 hasAuthorship W1905936601A5036707826 @default.
• W1905936601 hasAuthorship W1905936601A5041326568 @default.
• W1905936601 hasAuthorship W1905936601A5044377393 @default.
• W1905936601 hasAuthorship W1905936601A5049953201 @default.
• W1905936601 hasAuthorship W1905936601A5051084648 @default.
• W1905936601 hasAuthorship W1905936601A5061258831 @default.
• W1905936601 hasAuthorship W1905936601A5062095629 @default.
• W1905936601 hasAuthorship W1905936601A5066888430 @default.
• W1905936601 hasAuthorship W1905936601A5068718640 @default.
• W1905936601 hasAuthorship W1905936601A5082419868 @default.
• W1905936601 hasAuthorship W1905936601A5083934929 @default.
• W1905936601 hasAuthorship W1905936601A5084826357 @default.
• W1905936601 hasAuthorship W1905936601A5087080299 @default.
• W1905936601 hasAuthorship W1905936601A5088676411 @default.
• W1905936601 hasConcept C159654299 @default.
• W1905936601 hasConcept C185592680 @default.
• W1905936601 hasConcept C203014093 @default.
• W1905936601 hasConcept C21951064 @default.
• W1905936601 hasConcept C2777325958 @default.
• W1905936601 hasConcept C2780035454 @default.
• W1905936601 hasConcept C502942594 @default.
• W1905936601 hasConcept C542903549 @default.
• W1905936601 hasConcept C55493867 @default.
• W1905936601 hasConcept C70721500 @default.
• W1905936601 hasConcept C74187038 @default.
• W1905936601 hasConcept C86803240 @default.
• W1905936601 hasConcept C98274493 @default.
• W1905936601 hasConceptScore W1905936601C159654299 @default.
• W1905936601 hasConceptScore W1905936601C185592680 @default.
• W1905936601 hasConceptScore W1905936601C203014093 @default.
• W1905936601 hasConceptScore W1905936601C21951064 @default.
• W1905936601 hasConceptScore W1905936601C2777325958 @default.
• W1905936601 hasConceptScore W1905936601C2780035454 @default.
• W1905936601 hasConceptScore W1905936601C502942594 @default.
• W1905936601 hasConceptScore W1905936601C542903549 @default.
• W1905936601 hasConceptScore W1905936601C55493867 @default.
• W1905936601 hasConceptScore W1905936601C70721500 @default.
• W1905936601 hasConceptScore W1905936601C74187038 @default.
• W1905936601 hasConceptScore W1905936601C86803240 @default.
• W1905936601 hasConceptScore W1905936601C98274493 @default.
• W1905936601 hasLocation W19059366011 @default.
• W1905936601 hasOpenAccess W1905936601 @default.
• W1905936601 hasPrimaryLocation W19059366011 @default.
• W1905936601 hasRelatedWork W118157441 @default.
• W1905936601 hasRelatedWork W133786638 @default.
• W1905936601 hasRelatedWork W2007756994 @default.
• W1905936601 hasRelatedWork W2023578656 @default.
• W1905936601 hasRelatedWork W2069645292 @default.
• W1905936601 hasRelatedWork W2071163127 @default.
• W1905936601 hasRelatedWork W2091368548 @default.
• W1905936601 hasRelatedWork W2150244588 @default.
• W1905936601 hasRelatedWork W2183643866 @default.
• W1905936601 hasRelatedWork W2320895053 @default.
• W1905936601 hasRelatedWork W2734283637 @default.
• W1905936601 hasRelatedWork W2740434250 @default.
• W1905936601 hasRelatedWork W2741195625 @default.
• W1905936601 hasRelatedWork W2790219752 @default.
• W1905936601 hasRelatedWork W2889370697 @default.
• W1905936601 hasRelatedWork W2951278057 @default.
• W1905936601 hasRelatedWork W2958954217 @default.
• W1905936601 hasRelatedWork W3172820253 @default.
• W1905936601 hasRelatedWork W37501665 @default.

• next